Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Understanding Clinical Trial NCT05893888 — Plain Language Summary

This trial has multiple groups (called "Arms"). The criteria below are organised by group.

ARM 1 — Early-stage lip or oral cavity cancer (non-invasive/in situ)

Who might be able to join this trial:

• People with a confirmed diagnosis of very early-stage (non-invasive/in situ) cancer of the lip or oral cavity, proven by tissue testing
• People whose tissue samples show changes serious enough that doctors recommend surgery
• Adults aged 18 or older at the time of screening
• People whose tumor can be physically reached by doctors, with no signs of infection or active bleeding
• People whose tumor can be surgically removed within 8 weeks of the first screening visit
• People with a tumor that can be measured by physical examination or medical imaging
• People who are generally well enough to carry out basic daily activities (as assessed by a standard medical scale — confirm with trial site)
• People who are willing to use two forms of effective contraception from screening until at least 30 days after the last dose of the study treatment (this applies to people who could become pregnant)
• Women who could become pregnant must not be breastfeeding and must have a negative pregnancy blood test within 14 days before starting treatment
• People without serious underlying health conditions that would prevent participation
• People with an estimated life expectancy of at least 3 months
• People who are willing and able to sign a written consent form
• People who are able to return to the trial site for all required treatment and follow-up visits

Who may not be able to join:

• People who are not considered suitable candidates for standard surgical treatment
• People with a past history of invasive squamous cell carcinoma (a type of skin or tissue cancer)
• People whose tumor involves the gum tissue at the edge of the teeth (marginal gingiva)
• People who have previously received radiotherapy (radiation treatment) for squamous cell carcinoma of the mouth
• People who received systemic chemotherapy for head and neck squamous cell carcinoma within the past 2 years
• People who currently have another cancer diagnosis (except for certain limited skin cancers — confirm with trial site)
• People who have taken part in another clinical trial using an experimental treatment within the past 3 months
• People with a known allergy or serious reaction to platinum-based medicines, or who previously could not tolerate a platinum-based treatment
• People with an active, uncontrolled infection (such as HIV, syphilis, hepatitis B, or hepatitis C) that requires ongoing treatment
• People with another serious, uncontrolled illness that could affect their safety or ability to follow the trial requirements
• People who are pregnant, planning to become pregnant, or currently breastfeeding
• People with a medical or psychiatric condition that may affect their ability to give written informed consent
• People with a diagnosed condition causing scarring inside the mouth (oral submucous fibrosis)
• People with a diagnosed condition causing difficulty opening the mouth (trismus)

ARM 2 — More advanced lip or oral cavity cancer (T1–T3, no distant spread)

Who might be able to join this trial:

• People with a confirmed diagnosis of lip or oral cavity cancer classified as T1 to T3 stage with no confirmed distant spread, proven by tissue testing
• All other inclusion criteria are the same as Arm 1 above

Who may not be able to join:

• All exclusion criteria are the same as Arm 1 above, except the following do not apply to Arm 2: prior invasive squamous cell carcinoma history, tumors involving marginal gingiva, prior radiotherapy for oral squamous cell carcinoma, prior chemotherapy within 2 years, oral submucous fibrosis, and trismus

ARM 3a — Oral cavity squamous cell carcinoma (injection-based treatment)

Who might be able to join this trial:

• Adults aged 18 or older at the time of screening
• People with a confirmed diagnosis of squamous cell carcinoma (a type of cancer) of the mouth, classified as clinical stage T1 to T3, with limited or no lymph node involvement and no spread to other parts of the body (including lip cancer with significant involvement of the inner mouth lining)
• People whose tumor can be physically reached for a direct injection into the tumor, with no signs of active infection
• People with a tumor that can be measured by physical examination or medical imaging
• People who are generally well enough to carry out basic daily activities (as assessed by a standard medical scale — confirm with trial site)
• People with an estimated life expectancy of at least 3 months
• People who are willing and able to sign a written consent form
• People who are able to return to the trial site for all required treatment visits
• People who could become pregnant must agree to use two effective methods of contraception during the study

Who may not be able to join:

• People who are not considered suitable candidates for standard surgical treatment
• People with abnormal kidney or liver function, as determined by the treating doctor
• People whose heart's electrical activity shows a specific irregularity on an ECG test (QTc above 470 ms for women or above 450 ms for men — confirm with trial site)
• People whose tumor has grown into bone (stage T4)
• People with a diagnosis of salivary gland cancer
• People who have a history of oral cancer that did not respond to radiation or platinum-based chemotherapy within the past 12 months
• People with cancer that has appeared in multiple separate locations in the mouth at the same time
• People who have taken part in another clinical trial using an experimental treatment within the past 3 months
• People with a known allergy or serious reaction to platinum-based medicines, or who previously could not tolerate a platinum-based treatment
• People with an active, uncontrolled infection (such as HIV, syphilis, hepatitis B, or hepatitis C) that requires ongoing treatment
• People with another serious, uncontrolled illness that could affect their safety or ability to follow the trial requirements
• People who are pregnant, planning to become pregnant, or currently breastfeeding
• People with a medical or psychiatric condition that may affect their ability to give written informed consent

ARM 3b — Lung tumors (primary or secondary)

Who might be able to join this trial:

• Adults aged 18 or older at the time of screening
• People with a confirmed diagnosis of a malignant (cancerous) tumor in the lung — either starting in the lung or spreading there from elsewhere — classified as stage T1 to T2, with no lymph node involvement and no spread to other parts of the body
• People whose tumor can be reached via a bronchoscope (a thin tube passed into the airways) for direct injection into the tumor, with no signs of active infection
• People with a tumor that can be measured by physical examination or medical imaging
• People who are generally well enough to carry out basic daily activities (as assessed by a standard medical scale — confirm with trial site)
• People with an estimated life expectancy of at least 3 months
• People who are willing and able to sign a written consent form
• People who are able to return to the trial site for all required treatment visits
• People who could become pregnant must agree to use two effective methods of contraception during the study

Who may not be able to join:

• People who are not considered suitable candidates for standard surgical treatment
• People with abnormal kidney or liver function, as determined by the treating doctor
• People whose heart's electrical activity shows a specific irregularity on an ECG test (QTc above 470 ms for women or above 450 ms for men — confirm with trial site)
• People whose tumor has grown into bone (stage T4)
• People who currently have another active cancer that requires systemic (whole-body) treatment
• People who have a history of lung cancer that did not respond to radiation or platinum-based chemotherapy within the past 12 months
• People who have taken part in another clinical trial using an experimental treatment within the past 3 months
• People with a known allergy or serious reaction to platinum-based medicines, or who previously could not tolerate a platinum-based treatment
• People with an active, uncontrolled infection (such as HIV, syphilis, hepatitis B, or hepatitis C) that requires ongoing treatment
• People with another serious, uncontrolled illness that could affect their safety or ability to follow the trial requirements
• People who are pregnant, planning to become pregnant, or currently breastfeeding
• People with a medical or psychiatric condition that may affect their ability to give written informed consent

Important: Always verify eligibility with the trial site directly before applying.